Segment Reporting - Schedule of Segment Net Loss, Including Disaggregated Components of Operating Expenses (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Segment Reporting Information [Line Items]
Collaboration revenue - related party	$ 2,370	$ 2,380
Research and development:
Personnel expenses (including stock-based compensation of $1,162 and $1,073, respectively)	9,911	7,588
Manufacturing costs	6,580	3,373
Professional fees and other	4,767	2,971
Total research and development expenses	62,966	31,799
General and administrative:
Personnel expenses (including stock-based compensation of $4,842 and $2,354, respectively)	10,842	6,352
Professional fees	4,349	3,347
Other (including depreciation of $89 and $60, respectively)	1,977	996
Total general and administrative expenses	17,168	10,695
Total operating expenses	80,134	42,494
Loss from operations	(77,764)	(40,114)
Other income (expense):
Change in fair value of preferred stock tranche right liabilities	2,859	15,527
Interest income	12,123	4,165
Other expense, net	(24)	(115)
Total other income, net	14,958	19,577
Net loss	(62,806)	(20,537)
Asthma Indication
Research and development:
Verekitug program	28,069	14,537
CRSwNP Indication
Research and development:
Verekitug program	10,524	$ 3,330
COPD Indication
Research and development:
Verekitug program	$ 3,115